Download PDF
Nervenheilkunde 2011; 30(04): 229-237
DOI: 10.1055/s-0038-1627801
Schizophrenie
Schattauer GmbH

Pharmakotherapie der Schizophrenie

Article in several languages: deutsch | English
H.-P. Volz
1   Krankenhaus für Psychiatrie, Psychotherapie und Psychosomatische Medizin Schloss Werneck, Werneck
,
O. Dietmaier
2   Zentrum für Psychiatrie, Psychotherapie und Kinder-und Jugendpsychiatrie, Klinikum am Weissenhof
› Author Affiliations
Further Information

Publication History

Eingegangen am: 30 June 2010

angenommen am: 31 August 2010

Publication Date:
23 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Die Auswahl des “richtigen” Antipsychotikums für einen schizophrenen Patienten ist eine komplexe Aufgabe. In dem Artikel werden die wichtigsten Auswahlkriterien in Bezug auf das hauptsächlich zu beeinflussende Zielsyndrom (Akut-/Langzeitbehandlung, Positiv-/Negativsymptomatik, depressive Symptomatik, kognitive Störungen) sowie im Hinblick auf Verträglichkeits- und Sicherheitsaspekte dargestellt.

Schlüsselwörter

Antipsychotika - Schizophrenie - Selektionskriterien
 

  • Literatur

  • 1 Allison DB. et al. Antipsychotic-induced weightgain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
    Google Scholar
  • 2 Amaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598-604.
    CrossrefGoogle Scholar
  • 3 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association of the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267-72.
    CrossrefGoogle Scholar
  • 4 APA, American Psychiatric Association. Practice Guideline for the treatment of patients with schizophrenia. second edition. Am J Psychiatry. 2004. 161(2).
    Google Scholar
  • 5 Baas H. Parkinson-Syndrom. In: Förstl H. (Hrsg). Therapie neuropsychiatrischer Erkrankungen im Alter. München: Urban & Fischer. 2001
    Google Scholar
  • 6 Carillo JA. et al. Role of the smoking-induced cytochrome P450 (CYP) 1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23: 119-27.
    CrossrefGoogle Scholar
  • 7 Csernansky JG, Mahmoud R, Brenner R. Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22.
    CrossrefGoogle Scholar
  • 8 Davis JM. Overview: maintenance therapy in psychiatry, I: schizophrenia. Am J Psychiatry 1975; 132: 1237-45.
    CrossrefGoogle Scholar
  • 9 Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985; 46: 18-21.
    Google Scholar
  • 10 Degner D. et al. Qtc-Zeit-Verlängerung unter Amitriptylin in Kombination mit Ziprasidon. Psychopharmakotherapie 2010; 17: 51-4.
    Google Scholar
  • 11 DGPPN (Hrsg).. S3-Praxisleitlinien in Psychiatrie und Psychotherapie, Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff-Verlag; 2006
    Google Scholar
  • 12 Falkai P. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 2005; 06: 132-91.
    CrossrefGoogle Scholar
  • 13 Fuchs WS. et al. Agranulozytose und Leukopenie unter Psychopharmaka mit Schwerpunkt Clozapin. Psychopharmakotherapie 2008; 15: 126-30.
    Google Scholar
  • 14 Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-82.
    CrossrefGoogle Scholar
  • 15 Green MF. et al. The neurocognitive effects of lowdose haloperidol: A two-year comparison with risperidone. Biol Psychiatry 2002; 51: 972-8.
    CrossrefGoogle Scholar
  • 16 Grimm SW. et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006; 61: 58-69.
    CrossrefGoogle Scholar
  • 17 Harvey PD, Green MF, Keefe RSE, Velligan DI. Cognitive functioning in schizophrenia: A consensus statement on its role in the definition and evaluation of affective treatments for the illness. J Clin Psychiatry 2004; 65: 361-72.
    CrossrefGoogle Scholar
  • 18 Hatta K. et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Res 2009; 113: 49-55.
    CrossrefGoogle Scholar
  • 19 Hiemke C. et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279-81.
    Google Scholar
  • 20 Kraus JE. et al. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. J Clin Psychiatry 2005; 66: 1564-8.
    CrossrefGoogle Scholar
  • 21 Lambreva E. et al. Neurotoxische Enzephalopathie unter Neuroleptika und Lithium. Nervenarzt 2005; 76: 756-9.
    CrossrefGoogle Scholar
  • 22 Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medication. Am J Psychiatry 2004; 161: 1709-11.
    CrossrefGoogle Scholar
  • 23 Leucht S. et al. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomised, controlled trials. Am J Psychiatry 2003; 160: 1209-22.
    CrossrefGoogle Scholar
  • 24 Leucht S. et al. Second generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
    CrossrefGoogle Scholar
  • 25 Leucht S, Kissling W, Davis JM. Second generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychological Medicine 2009; 39: 1591-602.
    CrossrefGoogle Scholar
  • 26 McCue R. et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Brit J Psychiatry 2006; 189: 433-40.
    CrossrefGoogle Scholar
  • 27 Messer T, Schmauß M. Polypharmazie in der Behandlung psychischer Erkrankungen. Wien: Springer; 2009
    Google Scholar
  • 28 Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004; 55: 1013-22.
    CrossrefGoogle Scholar
  • 29 Möller HJ. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms. Eur Arch Psychiatry Clin Neurosci 2001; 251: 217-24.
    CrossrefGoogle Scholar
  • 30 Murphy BP. et al. Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophrenia Res 2006; 88: 5-25.
    CrossrefGoogle Scholar
  • 31 NICE (National Institute for Clinical Excellence). 2003. Core Interventions in the Treatment of Schizophrenia. NICE, London. (www.nice.org.uk).
    Google Scholar
  • 32 Raja M, Azzoni A. Comparison of three antipsychotics in the emergency psychiatric setting. Hum Psychopharmacol 2003; 18: 447-52.
    CrossrefGoogle Scholar
  • 33 Rummel-Kluge C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews. 2006 3, Art. No.: CD005581.DOI:10.1002 /14651858.CD005581.pub2.
    Google Scholar
  • 34 Rupprecht alR. Zur Problematik der Kombination von Clozapin mit Benzodiazepinen. Nervenarzt 2004; 76: 857-60.
    Google Scholar
  • 35 Schäfer I, Lambert M, Naber D. Atypische Antipsychotika bei therapieresistenter Schizophrenie. Nervenarzt 2004; 75: 79-91.
    CrossrefGoogle Scholar
  • 36 Schneeweiss MD, Avorn J. Antipsychotic agents and sudden cardiac death – how should we manage the risk?. N Engl J Med 2009; 306: 294-6.
    Google Scholar
  • 37 Seppala NH. et al. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999; 85: 244-6.
    CrossrefGoogle Scholar
  • 38 Spina E. et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002; 22: 419-23.
    CrossrefGoogle Scholar
  • 39 Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000; 14: 409-18.
    CrossrefGoogle Scholar
  • 40 Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-4.
    CrossrefGoogle Scholar
  • 41 Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002; 56: 1-10.
    CrossrefGoogle Scholar
  • 42 Volz HP, Reischies F, Riedel M. Kognitive Störungen bei schizophrenen Patienten. Nervenarzt 2010; 81: 39-54.
    Google Scholar
  • 43 Volz HP, Dietmaier O. Welches Antipsychotikum für welchen Patienten. Der Neurologe und Psychiater 2010; 09 (09) 55-61.
    Google Scholar
  • 44 Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine´s effectiveness in schizophrenia: A systematic review and meta-analysis of randomised trials. Am J Psychiatry 1999; 156: 990-9.
    Google Scholar
  • 45 Woodward ND. et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 08: 457-72.
    CrossrefGoogle Scholar
  • 46 Zullino DF. et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002; 17: 141-3.
    CrossrefPubMedGoogle Scholar